electroCore, Inc. (NASDAQ:ECOR – Get Free Report)’s stock price shot up 1.1% during mid-day trading on Friday . The company traded as high as $11.75 and last traded at $11.53. 123,311 shares traded hands during mid-day trading, an increase of 509% from the average session volume of 20,244 shares. The stock had previously closed at $11.40.
electroCore Trading Up 1.1 %
The company has a 50-day moving average price of $7.55 and a 200 day moving average price of $6.73. The stock has a market capitalization of $74.33 million, a P/E ratio of -5.24 and a beta of 0.62.
electroCore (NASDAQ:ECOR – Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.01. electroCore had a negative net margin of 66.84% and a negative return on equity of 165.17%. The business had revenue of $6.14 million during the quarter, compared to analyst estimates of $5.85 million. During the same period in the prior year, the firm posted ($1.03) earnings per share. As a group, research analysts expect that electroCore, Inc. will post -1.32 earnings per share for the current year.
Insider Activity at electroCore
Institutional Trading of electroCore
A hedge fund recently raised its stake in electroCore stock. Renaissance Technologies LLC boosted its holdings in shares of electroCore, Inc. (NASDAQ:ECOR – Free Report) by 3.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 68,786 shares of the company’s stock after buying an additional 2,270 shares during the quarter. Renaissance Technologies LLC owned 1.15% of electroCore worth $442,000 at the end of the most recent reporting period. Institutional investors own 26.74% of the company’s stock.
About electroCore
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
Featured Articles
- Five stocks we like better than electroCore
- Dividend Capture Strategy: What You Need to Know
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.